Primary Effusion Lymphoma — Trials

Primary Effusion Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05907759	Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease	recruiting	Phase 2	40	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT02911142	Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma	active not recruiting	Phase 1 / Phase 2	17	National Cancer Institute (NCI)NIH	1	Aug 26, 2026